NCI-H69/LX20

Analysis of acquired drug resistance, study of small cell lung carcinoma, MDR studies.

Human Caucasian small cell lung carcinoma

The drug-resistant cell line NCI-H69/LX20 has been derived by exposure of the parent line, H69 (ECACC Number 91091802) to doxorubicin, also known as adriamycin. These multi drug resistant (MDR) cells have been found to be recognised by various anti-P-glycoprotein antibodies.

Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO₂; 37°C. It is recommended to culture the cells without drug upon resuscitation until the first passage. Resuscitate into 9 ml of medium. Immediately after resuscitation perform a centrifugation ste

RPMI 1640 + 2mM Glutamine + 2μg/ml Doxorubicin + 10% Foetal Bovine Serum (FBS). ECACC has found that the following supplement will assist good growth of cells: sodium selenite 10nM, Insulin 250ng/ml, Transferrin 10ug/ml and sodium pyruvate 1mM.

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.